Last reviewed · How we verify
The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1
To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
Details
| Lead sponsor | Vanderbilt University Medical Center |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 21 |
| Start date | 2007-04 |
| Completion | 2010-04 |
Conditions
- Metabolic Syndrome X
Interventions
- Eplerenone (Morning)
- Eplerenone (Night-time)
Primary outcomes
- Plasminogen Activator Inhibitor-1 (PAI-1) Levels — Baseline
baseline PAI-1 levels prior to drug administration - Plasminogen Activator Inhibitor-1 (PAI-1) Levels — after 6 weeks on Eplerenone
PAI-1 levels after Eplerenone 50mg daily for 2 weeks then 100mg daily for 4 weeks. Time of administration varied in the arms, either morning or night time dosing.
Countries
United States